JP2010515750A5 - - Google Patents

Download PDF

Info

Publication number
JP2010515750A5
JP2010515750A5 JP2009545669A JP2009545669A JP2010515750A5 JP 2010515750 A5 JP2010515750 A5 JP 2010515750A5 JP 2009545669 A JP2009545669 A JP 2009545669A JP 2009545669 A JP2009545669 A JP 2009545669A JP 2010515750 A5 JP2010515750 A5 JP 2010515750A5
Authority
JP
Japan
Prior art keywords
group
carbon atoms
groups
nitrogen
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2009545669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010515750A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/050695 external-priority patent/WO2008089015A1/en
Publication of JP2010515750A publication Critical patent/JP2010515750A/ja
Publication of JP2010515750A5 publication Critical patent/JP2010515750A5/ja
Abandoned legal-status Critical Current

Links

JP2009545669A 2007-01-11 2008-01-10 スフィンゴシン−1−ホスフェート(s1p)受容体アンタゴニスト生物活性を有する6−置換インドール−3−カルボン酸アミド化合物 Abandoned JP2010515750A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88447007P 2007-01-11 2007-01-11
PCT/US2008/050695 WO2008089015A1 (en) 2007-01-11 2008-01-10 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity

Publications (2)

Publication Number Publication Date
JP2010515750A JP2010515750A (ja) 2010-05-13
JP2010515750A5 true JP2010515750A5 (https=) 2011-03-03

Family

ID=39399972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009545669A Abandoned JP2010515750A (ja) 2007-01-11 2008-01-10 スフィンゴシン−1−ホスフェート(s1p)受容体アンタゴニスト生物活性を有する6−置換インドール−3−カルボン酸アミド化合物

Country Status (8)

Country Link
EP (1) EP2125723A1 (https=)
JP (1) JP2010515750A (https=)
KR (1) KR20090101307A (https=)
CN (1) CN101668741A (https=)
AU (1) AU2008206495A1 (https=)
CA (1) CA2674946A1 (https=)
MX (1) MX2009007334A (https=)
WO (1) WO2008089015A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524917B2 (en) * 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
WO2009117335A2 (en) * 2008-03-17 2009-09-24 Allergan, Inc. S1p3 receptor inhibitors for treating inflammation
EA019252B1 (ru) 2008-07-23 2014-02-28 Арена Фармасьютикалз, Инк. ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ (1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
SI2342205T1 (sl) 2008-08-27 2016-09-30 Arena Pharmaceuticals, Inc. Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj
SG10201906876PA (en) 2010-01-27 2019-09-27 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
SG183416A1 (en) 2010-03-03 2012-09-27 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
TWI522361B (zh) * 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
CN108602775B (zh) 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途
WO2018151834A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
CN110483437B (zh) * 2018-05-14 2022-12-06 嘉兴维眸生物科技有限公司 一种含五元环的化合物及其制备和应用
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
CN112955431A (zh) 2018-09-06 2021-06-11 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2121394A1 (fr) * 1971-01-08 1972-08-25 Anvar Procédé d'obtention de dérivés d'acides indole carboxyliques et produits préparables par ce procédé.
EP0146810A3 (de) 1983-12-05 1987-05-13 Solco Basel AG Verfahren zur Herstellung von Sphingosinderivaten
US5110987A (en) 1988-06-17 1992-05-05 Emory University Method of preparing sphingosine derivatives
ZA902794B (en) 1989-04-18 1991-04-24 Duphar Int Res New 3-n substituted carbamoyl-indole derivatives
US5294722A (en) 1992-04-16 1994-03-15 E. R. Squibb & Sons, Inc. Process for the preparation of imidazoles useful in angiotensin II antagonism
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
DE69728581D1 (de) * 1996-01-22 2004-05-13 Fujisawa Pharmaceutical Co Thiazolylbenzofuranderivate und ihre Verwendung als SRS-A- und Leukotrien-Antagonisten
AU6310198A (en) 1997-03-12 1998-09-29 Takara Shuzo Co., Ltd. Sphingosine analogues
WO1999012890A1 (fr) 1997-09-11 1999-03-18 Takara Shuzo Co., Ltd. Derives de sphingosine et composition medicamenteuse
DE19753522A1 (de) * 1997-12-03 1999-06-10 Boehringer Ingelheim Pharma Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel
IL144289A0 (en) * 1999-01-13 2002-05-23 Millennium Pharm Inc Functionalized heterocycles as chemokine receptor modulators
AU2001264313A1 (en) 2000-06-20 2002-01-02 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
DE60221391T2 (de) 2001-06-20 2008-04-17 Wyeth Substituierte indolsäurederivate als inhibitoren von plasminogen-aktivator-inhibitor-1 (pai-1)
JPWO2003070691A1 (ja) 2002-02-21 2005-06-09 財団法人大阪産業振興機構 N−ヒドロキシカルボキサミド誘導体
BRPI0707873A2 (pt) 2006-02-15 2011-05-10 Allergan Inc compostos amida, Éster, tioamida e tiol Éster do Ácido indol-3-carboxÍlico carregando grupos arila ou heteroarila tendo atividade biolàgica antagonista de recptor de esfingosina-1-fosfato (s1p)

Similar Documents

Publication Publication Date Title
JP2010515750A5 (https=)
RU2009102535A (ru) Производные карбамидов тропана, их получение и их применение в терапии
JP2011513305A5 (https=)
JP2013538801A5 (https=)
JP2018509418A5 (https=)
CA2565813A1 (en) Substituted methyl aryl or heteroaryl amide compounds
PE20110852A1 (es) Antagonistas del receptor de orexina de isonicotinamida
RU2007146798A (ru) ПРОИЗВОДНЫЕ 4-(2-АМИНО-1-ГИДРОКСИЭТИЛ)ФЕНОЛА КАК АГОНИСТЫ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
RU2009115963A (ru) Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами
NO20076418L (no) Heterocyclic compounds as agonists for the thyroid receptor
JP2013518129A5 (https=)
RU2008152180A (ru) ПРОИЗВОДНЫЕ ПИРРОЛА, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ CRTh2 РЕЦЕПТОРА
JP2011519374A5 (https=)
JP2011515398A5 (https=)
KR101360556B9 (ko) 글리코피롤레이트 및 베타2 아드레날린 수용체아고니스트의 조합물
CY1109493T1 (el) Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις
IL185844A0 (en) I-acetic acid-indole derivatives with pgd2 antagonist activity
JP2011515483A5 (https=)
JP2012513990A5 (https=)
RU2014122035A (ru) Соединения с нематоцидной активностью
AR062299A1 (es) Derivados de bencimidazol
RU2011108281A (ru) Трипиридилкарбоксамидные антагонисты орексиновых рецепторов
TW200734322A (en) Indole derivatives exhibiting PGD2 receptor antagonism
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20120655A1 (es) Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map)